Denis Lynch
Pfizer
6 Papers
25 Citations
Denis Lynch is an academic researcher from Pfizer. The author has contributed to research in topics: Stereocenter & Catalysis. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling
Shengquan Duan,David Place,Hahdi H. Perfect,Nathan D. Ide,Mark T. Maloney,Karen Sutherland,Wiglesworth Kristin,Ke Wang,Mark Olivier,Fangming Kong,Kyle R. Leeman,Jon Blunt,John Draper,Marie McAuliffe,Maria M. O’Sullivan,Denis Lynch +15 more
TL;DR: In this paper, the SNAr coupling between aminopyridine 3 and chloropyrimidine 7 was studied from a synthetic and mechanistic perspective, and Grignard bases were identified as the preferred class of bases for this reaction.
44
Synthesis of Filibuvir. Part I. Diastereoselective Preparation of a β-Hydroxy Alkynyl Oxazolidinone and Conversion to a 6,6-Disubstituted 2H-Pyranone
Robert A. Singer,John A. Ragan,Paul Bowles,Esmort Chisowa,Brian G. Conway,Eric M. Cordi,Kyle R. Leeman,Leo Joseph Letendre,Janice E. Sieser,Gregory W. Sluggett,Corey L. Stanchina,Holly Strohmeyer,Jon Blunt,Stuart Taylor,Ciaran Byrne,Denis Lynch,Sandra Mullane,Maria M. O’Sullivan,Marcella Whelan +18 more
TL;DR: In this article, the first in a series of three papers describing the identification and development of a commercial synthesis of filibuvir (1) was described, where the Evans aldol reaction was used to control the tertiary alcohol stereocenter, a challenging variant of that strategy in that both reacting partners were nonstandard (acetate enolate and ketone electrophile).
20
Development of a Practical and Efficient Synthesis of CP-945,598-01, a CB1 Antagonist for the Treatment of Obesity
John A. Ragan,Dennis E. Bourassa,Jon Blunt,Darragh Breen,Busch Frank R,Eric M. Cordi,David B. Damon,Nga M. Do,Alanya Engtrakul,Denis Lynch,Ruth E. McDermott,Joseph A. Mongillo,Maria M. O’Sullivan,Peter Robert Rose,Brian C. Vanderplas +14 more
TL;DR: In this article, an efficient bond-forming sequence and optimization of reaction conditions are described for the synthesis of CP-945,598-01 (1·HCl), a CB1 antagonist in clinical studies for the treatment of obesity.
16
Synthesis of Filibuvir. Part III. Development of a Process for the Reductive Coupling of an Aldehyde and a β-Keto-lactone
Nathan D. Ide,John A. Ragan,Gabriel Bellavance,Steve J. Brenek,Eric M. Cordi,Grace O. Jensen,Kris N. Jones,Danny Lafrance,Kyle R. Leeman,Leo Joseph Letendre,David Place,Corey L. Stanchina,Gregory W. Sluggett,Holly Strohmeyer,Jon Blunt,Kevin Meldrum,Stuart Taylor,Ciaran Byrne,Denis Lynch,Sandra Mullane,Maria M. O’Sullivan,Marcella Whelan +21 more
TL;DR: In this article, a reductive coupling of a β-keto-lactone and an aldehyde is described, in which the Hantzsch ester serves as an inexpensive and convenient reducing agent.
10
Palbociclib Commercial Manufacturing Process Development. Part II: Regioselective Heck Coupling with Polymorph Control for Processability
Mark T. Maloney,Brian P. Jones,Mark Olivier,Javier Magano,Ke Wang,Nathan D. Ide,Andrew S. Palm,David R. Bill,Kyle R. Leeman,Karen Sutherland,John Draper,Adrian M. Daly,Joseph Keane,Denis Lynch,Marie O’Brien,Joanne Tuohy +15 more
TL;DR: A three-step commercial manufacturing route has been developed for palbociclib, a highly selective, reversible inhibitor of CDK 4/6 as mentioned in this paper, which utilizes a Heck coupling to install the enol ether side chain.